NSE: LUPIN | BSE: 500257

Mid-range Performer

Download real time

2001.60 -2.80 (-0.14%)

43,351 NSE+BSE Volume

NSE 23 Sep, 2025 9:45 AM (IST)

91,424

Market Cap

High in industry

0.9

Beta 1Year

Low volatility

US FDA Observation

Lupin's Pune biotech facility receives Form 483 with four observations from the US FDA See details

Lupin Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LUPIN, BSE:500257 Lupin Ltd.

Lupin Ltd.

20 May 2022

2001.60

-0.14%

Lupin Ltd

Hold: Lupin Ltd.

ICICI Direct

Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.

Lupin Ltd.

09 Feb 2022

2001.60

-0.14%

LUPIN LIMITED

Hold: Lupin Ltd.

Target

Geojit BNP Paribas

Lupin Limited is a multi-national pharmaceutical company based in Mumbai. The company specializes in branded and generic formulations, API's and advanced drug delivery systems in the area of biotechnology. The...

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

07 Feb 2022

2001.60

-0.14%

Result Update:Lupin

Hold: Lupin Ltd.

Recommendation Target

Axis Direct

We expect a near-term headwind for Lupin and therefore recommend a HOLD rating with a target price of Rs 950.

Lupin Ltd. is trading above its 150 day SMA of 1980.4

Lupin Ltd.

05 Feb 2022

2001.60

-0.14%

Niche launches and cost optimization key to a turnaround

Neutral: Lupin Ltd.

Target

Motilal Oswal

3QFY22 miss led by business mix and lower operating leverage LPC delivered a lower than expected 3QFY22 financial performance, led by moderate growth in the US and India and higher price erosion and raw material cost. While the management continues its efforts towards building a complex pipeline and working on cost optimization measures, a meaningful benefit is expected from 2HFY23 onwards. We have cut our FY22E/FY23E/FY24E EPS estimate by 12%/26%/23% to reflect: a) lower offtake of seasonal products in the US, b) reduced demand...

Lupin Ltd. is trading below its 200 day SMA of 2025.5

Lupin Ltd.

05 Feb 2022

2001.60

-0.14%

Lupin (SELL): Major benefits remain back ended, 3Q disappoints

Sell: Lupin Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Q3 revenue growth modest at 4% YoY (+2% QoQ) despite strong US and India formulation business, as API revenue declined 25%

Lupin Ltd. is trading below its 200 day SMA of 2025.5

Lupin Ltd.

14 Dec 2021

2001.60

-0.14%

USFDA regulatory hurdle crossed at Goa

Neutral: Lupin Ltd.

Target

Motilal Oswal

Learnings at Goa to enhance remediation measures at other sites as well After almost 4.5 years of regulatory hurdles, LPC received a favorable classification (Voluntary Action Indicated or VAI) for its Goa facility from the USFDA. This is a big relief from a compliance standpoint, given the reasonable contribution in the base business as well as double digit ANDAs pending approval from the Goa site. We expect 21% earnings CAGR over FY21-23E and raise our 12-month forward P/E to 25x (to factor Goa compliance) from 24x earlier and arrive at our TP to INR990/share. While the regulatory clearance removes a key overhang on the Goa...

Lupin Ltd. is trading below its 200 day SMA of 2025.5

Lupin Ltd.

14 Dec 2021

2001.60

-0.14%

Lupin Ltd

Hold: Lupin Ltd.

ICICI Securities Limited

About the stock: Lupin is a multinational pharma company engaged in manufacturing & marketing branded & generic formulations, APIs, biotech products as well as OTC medicines across multiple dosage forms & therapeutic categories....

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

08 Nov 2021

2001.60

-0.14%

LUPIN LIMITED

Hold: Lupin Ltd.

Target

Geojit BNP Paribas

Lupin Ltd. is trading below its 200 day SMA of 2025.5

Lupin Ltd.

29 Oct 2021

2001.60

-0.14%

Q2FY22 Result Update - On the path of gradual recovery - ACCUMULATE

Accumulate: Lupin Ltd.

Recommendation Target

Prabhudas Lilladhar

Lupin's (LPC) H1 profitability was soft on account of low US sales and weak GMs. We believe recovery in US sales will be gradual and may hinge on market share gains in gAlbuterol with timely niche launches. Also, strong inhalation pipeline and biosimilar franchise provides visibility beyond FY22. Further, margins will improve in H2FY22/FY23 with likely savings in promotional expenses related to Solosec and rationalization of R&D expenses. We expect 21% EPS CAGR over FY21-24E and recommend Accumulate' with TP of Rs 1,004/share, 23x Sept 2023E EPS....